Drug Name |
Betahistine |
Drug ID |
BADD_D00258 |
Description |
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408]
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to reduce symptoms through its actions on histamine receptors.[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. It is currently marketed in Canada by various companies, including Teva Pharmaceuticals. |
Indications and Usage |
Betahistine is indicated for the reduction of recurrent vertigo episodes associated with Ménière's disease in patients 18 years old and above.[L16388] |
Marketing Status |
approved; investigational |
ATC Code |
N07CA01 |
DrugBank ID |
DB06698
|
KEGG ID |
D07522
|
MeSH ID |
D001621
|
PubChem ID |
2366
|
TTD Drug ID |
D0XW9U
|
NDC Product Code |
Not Available |
UNII |
X32KK4201D
|
Synonyms |
Betahistine | Aequamen | Betahistin-Ratiopharm | Betahistin Ratiopharm | Betahistine Dihydrobromide | Dihydrobromide, Betahistine | Betahistine Hydrochloride | Hydrochloride, Betahistine | Betahistine Dihydrochloride | Dihydrochloride, Betahistine | Betahistine Mesylate | Mesylate, Betahistine | Betahistine Methanesulphonate | Methanesulphonate, Betahistine | Betahistine Methanesulfonate | Methanesulfonate, Betahistine | Betavert | By-Vertin | By Vertin | Extovyl | Fidium | Lectil | Melopat | Mersilon | PT-9 | PT 9 | PT9 | Ribrain | Serc | Betaserc | Vasomotal | Betahistine Biphar | Vertigon | Betahistin AL | Betahistin Stada |